The Food and Drug Administration (FDA) recently gave approval to the first new mesothelioma drug treatment combination for patients in the last 16 years. The drug combination, Opdivo (nivolumab) in combination with Yervoy (ipilimumab) are a first-line treatment for adults with malignant pleural mesothelioma that cannot be removed by surgery.…
A Sweedish pharmaceutical company recently announced it has seen positive results with a therapeutic cancer vaccine that could potentially be used in combination with other immuno-oncology drugs to treat metastatic malignant mesothelioma. The results of the clinical trials showed that more than half of the participants did not demonstrate disease…
A recently published Japanese study conducted by university oncologists shows improved outcomes for certain mesothelioma patients who undergo near-infrared irradiation treatment used in combination with a cancer-targeting compound. The experiment, which was conducted on laboratory mice, as well as human cells with malignant mesothelioma found that near-infrared photoimmunotherapy was an…
A recent study examining a new therapy in an emerging cancer treatment known as T-cell therapy has shown positive results, according to an executive with the clinical-stage immunotherapy company that developed the treatment. Developed by TCR2 Therapeutics Inc., TC-210 TRuC-T cell products were given to five mesothelioma cancer patients who…
A recent analysis published in the Annals of Surgical Oncology determined that peritoneal mesothelioma patients who underwent surgery had a far better survival rate compared to those who did not have surgical intervention to treat their cancer. The study analyzed the survival rates of over 2,000 patients diagnosed with peritoneal…
A recently published study from the Netherlands appears to indicate that a combination of a pair of immunotherapy drugs can help improve the prognosis of mesothelioma patients with tumors that are not able to be removed through surgery. The experiment, named checkmate 743, compared the use of first-line nivolumab and…
A recently published study by Japanese researchers appears to show that a novel type of cancer immunotherapy helped shrink tumors in lab mice, which could bode as a promising treatment for mesothelioma cancer and other serious types of cancers. The study examined the use of near-infrared photoimmunotherapy, a type of…
A recent study published by an international team of researchers examined the safety and efficacy of radiation treatments for patients diagnosed with mesothelioma cancer in pleural lining of their lungs, known as pleural mesothelioma. In their study, the radiation oncology experts determined that proton therapy for mesothelioma cancer of the…
A recent study by U.S. researchers has found that despite projections, pleural mesothelioma diagnosis rates would decline early this century, the data analyzed over a 10-year period suggests that diagnosis rates have remained steady. Fortunately, the data looked at also suggests that survival rates of pleural mesothelioma patients have improved…
The U.S. Food and Drug Administration (FDA) recently granted final approval of a new brand of a chemotherapy drug already in use by oncologists to treat malignant pleural mesothelioma and advanced stage non small cell lung cancer. Starting in February 2020, doctors will be allowed to prescribe Pemfexy, a type…